TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences priced an upsized public offering of 1,945,000 common shares at $90 per share for gross proceeds of $175.05 million. The company plans to use net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as phase 1 trials for BMB-105. The offering is expected to close on January 9, 2026.

Insights
AGX   positive

Company demonstrates strong financial health with low LTV ratios, high Interest Coverage Ratio, and a stable Investment Grade credit rating, indicating robust financial management and strategic planning for upcoming bond refinancing


DRUG   positive

The company successfully upsized its public offering from $100 million to $175 million, demonstrating strong investor demand. The offering will fund advancement of clinical trials for multiple drug candidates, including BMB-101 which showed positive Phase 2 results with significant anti-seizure benefits. This capital raise supports pipeline expansion and R&D acceleration.